{
    "paper_id": "00e4ab7411b97cde951b3aad2e20113c1953fadf",
    "metadata": {
        "title": "Journal Pre-proof Novel SARS-CoV-2 variants: the pandemics within the pandemic Novel SARS-CoV-2 variants: the pandemics within the pandemic 1 Manuscript Type: Narrative review Running Title: SARS-CoV-2 variants",
        "authors": [
            {
                "first": "Erik",
                "middle": [],
                "last": "Boehm",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Geneva University Hospitals",
                    "location": {
                        "postCode": "1205",
                        "settlement": "Geneva",
                        "country": "4 Switzerland"
                    }
                },
                "email": ""
            },
            {
                "first": "Ilona",
                "middle": [],
                "last": "Kronig",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Geneva University Hospitals",
                    "location": {
                        "postCode": "1205",
                        "settlement": "Geneva",
                        "country": "4 Switzerland"
                    }
                },
                "email": ""
            },
            {
                "first": "Richard",
                "middle": [
                    "A"
                ],
                "last": "Neher",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Laboratory of Virology, Division of Laboratory Medicine",
                    "institution": "University of Geneva",
                    "location": {
                        "postCode": "1205",
                        "settlement": "Geneva",
                        "country": "Switzerland"
                    }
                },
                "email": ""
            },
            {
                "first": "Isabella",
                "middle": [],
                "last": "Eckerle",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Geneva University Hospitals",
                    "location": {
                        "postCode": "1205",
                        "settlement": "Geneva",
                        "country": "4 Switzerland"
                    }
                },
                "email": ""
            },
            {
                "first": "Pauline",
                "middle": [],
                "last": "Vetter",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Geneva University Hospitals",
                    "location": {
                        "postCode": "1205",
                        "settlement": "Geneva",
                        "country": "4 Switzerland"
                    }
                },
                "email": ""
            },
            {
                "first": "Laurent",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Kaiser",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Geneva University Hospitals",
                    "location": {
                        "postCode": "1205",
                        "settlement": "Geneva",
                        "country": "4 Switzerland"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "Background: Many new variants of SARS-CoV-2 have been termed Variants of Concern/Interest (VOC/I) 20 because of their greater risk due to possibly: enhanced transmissibility and/or severity, immune escape, 21 diagnostic and/or treatment failure, and reduced vaccine efficacy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Objectives: We sought to review current knowledge of emerging SARS-CoV-2 variants, particularly those 23 deemed VOC/Is: B.1.351, B.1.1.7, and P.1.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Sources: MEDLINE and BioRxiv databases, as well as the grey literature were searched for reports of SARS-25 CoV-2 variants since November 2020. Relevant articles and their references were screened. 26 Content: Mutations on the spike protein in particular may affect both affinity for the SARS-CoV-2 cell receptor 27 ACEII or antibody binding. These VOC/Is often share similar mutation sets. The N501Y mutation is shared by 28 the main three VOCs: B.1.1.7, first identified in the United Kingdom; P.1, originating from Brazil; and B.1.351, 29 first described in South Africa. This mutation likely increases transmissibility, by increasing affinity for ACEII.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "30 The B.1.351 and P.1 variants also display the E484K mutation, which decreases binding of neutralizing 31 antibodies, leading to partial immune escape, favoring reinfections, and decreased in vitro efficacy of some 32 antibody therapies or vaccines. Those mutations may also have phenotypical repercussions of higher 33 severity. Furthermore, the accumulation of mutations poses a diagnostic risk (lowered when using multiplex 34 assays), as seen for some assays targeting the S-gene. With ongoing surveillance, many new VOC/Is have 35 been identified. The emergence of the E484K mutation independently in different parts of the globe may 36 reflect adaptation of SARS-CoV-2 to humans in a background of increasing immunity. 37 Implications: These VOC/Is are increasing in frequency globally and pose challenges to any herd immunity 38 approach of managing the pandemic. While vaccination is ongoing, vaccine updates may be prudent. The 39 virus continues to adapt to transmission in humans, and further divergence from the initial Wuhan sequences 40 is expected. 41 42 J o u r n a l P r e -p r o o f 65 effectiveness of public health and social measures or available diagnostics, vaccines, and therapeutics[5].",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "66 Here we describe variants meeting the definition of VOC and VOI as of March 2021, and discuss their known 67 characteristics. 68 69 Sources 70 J o u r n a l P r e -p r o o f",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "The evolutionary rate of SARS-CoV-2 is low (approximately 1 x10 -3 substitutions/site/year) thanks to its proof-44 reading RNA polymerase. This represents a fixation of 1 to 2 nucleotide changes per month per lineage, in the 45 30 ,000 base pairs of the virus [1] . These deletions, insertions or substitutions of nucleotides may either be 46 synonymous, with few or no repercussions to the virus, or non-synonymous, leading to a change in the amino- ",
            "cite_spans": [
                {
                    "start": 228,
                    "end": 230,
                    "text": "30",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 260,
                    "end": 263,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "ref_spans": [],
            "section": "43"
        },
        {
            "text": "Early in the pandemic, the D614G mutation of S arose and is now found in nearly every sequence worldwide, 57 likely due to epidemiological factors and a transmission advantage. In summer 2020, a variant spreading in 58 minks accumulated numerous mutations, while retaining the potential to infect humans, which led to the 59 slaughtering of Danish mink populations [4] .",
            "cite_spans": [
                {
                    "start": 365,
                    "end": 368,
                    "text": "[4]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "56"
        },
        {
            "text": "By the end of December 2020, new variants have emerged that have accumulated multiple mutations, called 61 \"Variants of interest\" (VOI) because they lead to phenotypic modifications, or have genomic mutations 62 suspected to lead to such modifications, and have been identified in multiple transmission events or in 63 multiple countries. \"Variants of concern\" (VOCs) have additionally been demonstrated to be associated with 64 increased transmissibility, increased virulence or changes in clinical disease presentation, or decreased We searched the MEDLINE and BioRxiv databases for reports of SARS-CoV-2 variants since November 71 2020. The grey literature, including Google database and Twitter was surveyed using the same keywords.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "60"
        },
        {
            "text": "Search terms used in various combinations were as follows: \"SARS-CoV-2\", \"variants\", \"variants of concern\", 73 \"VOC\", \"variants of interest\", \"VOI\", \"mutations\", \"evolution\", \"B.1.1.7\", \"B.1.351\", \"P.1\", \"B.1.148\", \"B.1.1.28\", 74 \"N501Y\", \"E484K\", and \"L452R\". We screened all articles identified and relevant references cited in those 75 articles.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "72"
        },
        {
            "text": "An overview of the new VOCs and VOIs is given in Table 1 . Lineage names, as determined by Pango 78 (https://cov-lineages.org/descriptions.html) and characterised by a combination of genetic and epidemiological 79 support, are commonly used; as are names given upon first identification [6] .",
            "cite_spans": [
                {
                    "start": 287,
                    "end": 290,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                }
            ],
            "ref_spans": [
                {
                    "start": 49,
                    "end": 56,
                    "text": "Table 1",
                    "ref_id": "TABREF1"
                }
            ],
            "section": "77"
        },
        {
            "text": "The number of new mutations accumulated by many of these VOCs and VOIs before detection is rather high.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "80"
        },
        {
            "text": "For some, the apparent lack of intermediates suggests a long period of undetected replication and evolution, 82 which may be explainable by: intra-host-evolution during a long chronic infection, poor monitoring, ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "81"
        },
        {
            "text": "A number of divergent sequences were identified in humans who had been in contact with minks [8] , and 92 attributed to adaptation to mink hosts, suggesting that the role of human to animal to human transmission 93 chains need to be carefully considered. Notably, some mink-associated variants resulted in partial escape 94 from neutralizing antibodies[9], emphasizing that the emergence of immune escape mutations does not 95 necessarily mean that emergence of these variants is due to selection pressure from human population-level 96 immunity. Transmission of these variants have been contained[10], likely due to efforts to culling mink 97 populations. Nonetheless, there remains a risk of further outbreaks from mink and other farmed or domestic 98 J o u r n a l P r e -p r o o f animals. It must be kept in mind that novel variants may be concerning not just for their effects in humans and 99 human to human transmissibility, but also their ability to establish animal reservoirs of SARS-CoV-2 and the 100 potentially elevated transmission due to a human-animal-human route [11] .",
            "cite_spans": [
                {
                    "start": 93,
                    "end": 96,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 1081,
                    "end": 1085,
                    "text": "[11]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "91"
        },
        {
            "text": "102 Several combined mutations define each new lineage (Table 2) . When occurring on S and especially on its 103 RBD, these mutations may affect receptor or antibody binding. The following mutations are particularly 104 noteworthy:",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 55,
                    "end": 64,
                    "text": "(Table 2)",
                    "ref_id": "TABREF2"
                }
            ],
            "section": "Notable mutations"
        },
        {
            "text": "The N501Y mutation, within the RBD of S, results in greater affinity for human ACE2 receptor[12], which may 106 increase transmissibility.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "105"
        },
        {
            "text": "The E484K mutation, also in the RBD of S, is associated with immune escape[13] and increased ACE2 108 affinity [14] . Notably, a similar mutation, E484Q, was also associated with immune escape [13] . with mutations in S are a concern for various antibody mediated therapies such as etesivimab (LY-CoV016), 126 bamlanivimab, casirivimab(REGN10933) [17, 22] . Resistance to specific monoclonal antibodies or resistance 127 due to a single mutation is unlikely to significantly affect neutralizing activity of polyclonal sera, while multiple 128 mutations may have more substantial effects; which is supported by studies using vaccine sera and 129 pseudovirus (PsV) [23] . No single mutation identified so far would be sufficient to abolish neutralizing activity, 130 so we can expect that current vaccines and exposure to other variants will still provide some degree of 131 protection. Notably, neutralization studies give no indication on the effectiveness of cell-mediated immunity 132 elicited after vaccination, which also contributes to protection against COVID-19. Indeed, the vast majority of ",
            "cite_spans": [
                {
                    "start": 111,
                    "end": 115,
                    "text": "[14]",
                    "ref_id": null
                },
                {
                    "start": 193,
                    "end": 197,
                    "text": "[13]",
                    "ref_id": null
                },
                {
                    "start": 347,
                    "end": 351,
                    "text": "[17,",
                    "ref_id": null
                },
                {
                    "start": 352,
                    "end": 355,
                    "text": "22]",
                    "ref_id": null
                },
                {
                    "start": 663,
                    "end": 667,
                    "text": "[23]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "107"
        },
        {
            "text": "Immune escape concerns: This variant contains a few mutations linked with potential immune escape (Table   152 2) and convalescent plasma or vaccine sera show reductions in neutralizing antibody titers; although 153 J o u r n a l P r e -p r o o f neutralization generally remains robust (Supplemental Table 1 ). There is no evidence of elevated reinfection 154 rates [30] , and current vaccines largely retain their effectiveness against it (Table 3) (Table 4 ). Furthermore, 189 serology and epidemiological studies indicated that 1/3 of the population had previously been exposed to Table 1 ). Preliminary data showed a complete escape from neutralization by ",
            "cite_spans": [
                {
                    "start": 367,
                    "end": 371,
                    "text": "[30]",
                    "ref_id": "BIBREF29"
                }
            ],
            "ref_spans": [
                {
                    "start": 98,
                    "end": 110,
                    "text": "(Table   152",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 301,
                    "end": 308,
                    "text": "Table 1",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 441,
                    "end": 450,
                    "text": "(Table 3)",
                    "ref_id": "TABREF3"
                },
                {
                    "start": 451,
                    "end": 459,
                    "text": "(Table 4",
                    "ref_id": "TABREF4"
                },
                {
                    "start": 585,
                    "end": 592,
                    "text": "Table 1",
                    "ref_id": "TABREF1"
                }
            ],
            "section": "151"
        },
        {
            "text": "Immune escape concerns: Sera neutralization is reportedly decreased (Supplemental Table 1 ), and the 229 L452R mutation has been reported to escape neutralization by bamlanivimab. ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 82,
                    "end": 89,
                    "text": "Table 1",
                    "ref_id": "TABREF1"
                }
            ],
            "section": "228"
        },
        {
            "text": "D253G mutation is also notable, and believed to play a role in immune escape.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "238"
        },
        {
            "text": "Diagnostic Impact: No data, but no issues are expected. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "239"
        },
        {
            "text": "Immune escape concerns: Both the E484Q and L452R mutations are a cause for concern of immune escape.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "256"
        },
        {
            "text": "Diagnostic Impact: No data, likely unaffected.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "257"
        },
        {
            "text": "The presence of the E484K mutation by itself should be enough to qualify a variant for VOI status, and the 260 known instances of variants with the E484K are too numerous to list here, but include: P.2, P.3, some isolates 261 of A. 23.1 and B.1.111, B.1.525, B.1.619, N.9, N.10, and A. VOI.V2. Data on these variants are scarce, but the 262 presence of the E484K mutation raises concerns of immune escape. Many of these variants are temporally 263 linked to a surge in cases, but their emergence may be an effect rather than a cause of such surges.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 232,
                    "end": 285,
                    "text": "23.1 and B.1.111, B.1.525, B.1.619, N.9, N.10, and A.",
                    "ref_id": "FIGREF39"
                }
            ],
            "section": "259"
        },
        {
            "text": "J o u r n a l P r e -p r o o f P.3 is also notable for containing the N501Y mutation that is found in the 3 variants classified as 265 VOCs by the WHO, which has been linked to increased ACEII affinity/transmissibility, ability to use rat and New variants, sharing some common mutations, emerged independently across the world in a background of 295 increasing population immunity, and rapidly spread in the area where they were identified. In many ways this 296 mirrors the early independent emergence and spread of D614G mutations. Their mutations likely render them 297 more transmissible (e.g. N501Y), with some ability to escape previous immunity (e.g. E484K), and may be 298 able to effectively establish infections in animals that are routinely in close proximity to humans. This was to 299 be expected given the number of infections across the world, and that the virus has only been adapting to 300 human transmission for a short time. While vaccination strategies aim to reduce the burden of COVID-19, the 301 efficacy of the vaccines may be reduced by the emergence of these new mutations, but two doses may still 302 protect against severe COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "264"
        },
        {
            "text": "With the increase of worldwide genome sequencing surveillance, the number of new identified variants is 304 expected to increase. Surveillance of all new identified variants has to be closely monitored, in order to be 305 able to take necessary countermeasures as soon as possible.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "303"
        },
        {
            "text": "Acknowledgments 307 We thank Manuel Schibler and Samuel Cordey for their meaningful advice. (Unk E)  --------+  ------T19R, G142D, E154K, E156G, \u2206157-158, V382L, N440T, 950N,  Q1071H, H1101D, D1153Y: Unk E   --------------+/-T20N, P26S, D138Y, R190S, T1027I: Unk E  --+  ------------S31F, S50L, P384L, A1070S: Unk E  -------------+/--Q52R, F888L: Unk E  ------+  --------H66D, G142V, G669S, Q949R, N1187D: Unk E  -----------+ I210N, \u2206211, \u2206247-249, W258L, R346K, Q957H : J o u r n a l P r e -p r o o f",
            "cite_spans": [
                {
                    "start": 16,
                    "end": 19,
                    "text": "307",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 92,
                    "end": 425,
                    "text": "(Unk E)  --------+  ------T19R, G142D, E154K, E156G, \u2206157-158, V382L, N440T, 950N,  Q1071H, H1101D, D1153Y: Unk E   --------------+/-T20N, P26S, D138Y, R190S, T1027I: Unk E  --+  ------------S31F, S50L, P384L, A1070S: Unk E  -------------+/--Q52R, F888L: Unk E  ------+  --------H66D, G142V, G669S, Q949R, N1187D: Unk E  -----------+",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 426,
                    "end": 468,
                    "text": "I210N, \u2206211, \u2206247-249, W258L, R346K, Q957H",
                    "ref_id": "FIGREF39"
                }
            ],
            "section": "306"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Phylogenetic and phylodynamic analyses of SARS-CoV-2. 336 Virus Res",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Nie",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "287",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Human neutralizing antibodies elicited by SARS-CoV-2 338 infection",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Ju",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Ge",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Ge",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "584",
            "issn": "7819",
            "pages": "115--124",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "N-terminal domain antigenic 340 mapping reveals a site of vulnerability for SARS-CoV-2. bioRxiv",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Mccallum",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "D"
                    ],
                    "last": "Marco",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Lempp",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Tortorici",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Pinto",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Walls",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "341",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "SARS-CoV-2 spike mutations arising in Danish mink and their spread to 342 humans",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Lassauni\u00e8re",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Fonager",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "COVID-19 Weekly Epidemiological Update",
            "authors": [],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "A dynamic nomenclature proposal 346 for SARS-CoV-2 lineages to assist genomic epidemiology",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Rambaut",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "C"
                    ],
                    "last": "Holmes",
                    "suffix": ""
                },
                {
                    "first": "\u00c1",
                    "middle": [],
                    "last": "O&apos;toole",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Hill",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "T"
                    ],
                    "last": "Mccrone",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Ruis",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature Microbiology",
            "volume": "5",
            "issn": "11",
            "pages": "1403--1410",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "SARS-CoV-2 350 Transmission between Mink (Neovison vison) and Humans, Denmark. Emerg Infect Dis",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Hammer",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Quaade",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "B"
                    ],
                    "last": "Rasmussen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Fonager",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Rasmussen",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Mundbjerg",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "27",
            "issn": "",
            "pages": "547--51",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Effect of RBD mutation (Y453F) in spike glycoprotein of SARS-CoV-2 on 353 neutralizing antibody affinity. bioRxiv",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Hayashi",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Yaegashi",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Konishi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "COVID mink analysis shows mutations are not dangerous -yet",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mallapaty",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "587",
            "issn": "",
            "pages": "340--341",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Assessing the Risks of SARS-CoV-2 357 in Wildlife",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Delahay",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Smith",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Sharun",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Snary",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "F"
                    ],
                    "last": "Giron",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the 360 human ACE2 receptor: insights from molecular dynamics simulations",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Luan",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Huynh",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "FEBS Letters",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Complete Mapping of Mutations to 364 the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Greaney",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "N"
                    ],
                    "last": "Starr",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Gilchuk",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "J"
                    ],
                    "last": "Zost",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Binshtein",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "N"
                    ],
                    "last": "Loes",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Cell Host Microbe",
            "volume": "365",
            "issn": "1",
            "pages": "44--57",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Molecular dynamic simulation 367 reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and 368 N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, 369 potentially resulting in an escape mutant. bioRxiv",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Nelson",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Buzko",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "R"
                    ],
                    "last": "Spilman",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Niazi",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Rabizadeh",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "R"
                    ],
                    "last": "Soon-Shiong",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind 371 human ACE2 with increased affinity. bioRxiv",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Khavari",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ramanathan",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "D"
                    ],
                    "last": "Ferguson",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Miao",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Emergence of a Novel SARS-CoV-373 2 Variant in Southern California",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "D"
                    ],
                    "last": "Davis",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "S"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Sincuir",
                    "middle": [],
                    "last": "Martinez",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Plummer",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "T"
                    ],
                    "last": "Vail",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Complete map of SARS-CoV-2 RBD mutations that escape 376 the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "N"
                    ],
                    "last": "Starr",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Greaney",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Dingens",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Bloom",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Cell Reports Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Recurrent 379 deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "R"
                    ],
                    "last": "Mccarthy",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "J"
                    ],
                    "last": "Rennick",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Nambulli",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "R"
                    ],
                    "last": "Robinson-Mccarthy",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "G"
                    ],
                    "last": "Bain",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Haidar",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Science",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Recurrent emergence and 383 transmission of a SARS-CoV-2 Spike deletion H69/V70. bioRxiv",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Kemp",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Meng",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Ferriera",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "P"
                    ],
                    "last": "Datir",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "T"
                    ],
                    "last": "Harvey",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Collier",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Novel variants of SARS-CoV-2 and the impact on diagnostic testing",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Emergence of N antigen 387 SARS-CoV-2 genetic variants escaping detection of antigenic tests. medRxiv",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "D"
                    ],
                    "last": "Vecchio",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Brancaccio",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "R"
                    ],
                    "last": "Brazzale",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Lavezzo",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Onelia",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Franchin",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "SARS-CoV-2 variants B.1.351 and 390 B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination. 391 bioRxiv",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hoffmann",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Arora",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Gross",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Seidel",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hoernich",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Hahn",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "mRNA vaccine-elicited 393 antibodies to SARS-CoV-2 and circulating variants",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Schmidt",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Weisblum",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Muecksch",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "O"
                    ],
                    "last": "Barnes",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Finkin",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Nature",
            "volume": "",
            "issn": "",
            "pages": "1--7",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Negligible impact of SARS-CoV-2 395 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees. bioRxiv",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Tarke",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Sidney",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Methot",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Dan",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Goodwin",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Estimated transmissibility 398 and impact of SARS-CoV-2 lineage B.1.1.7 in England",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "G"
                    ],
                    "last": "Davies",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Abbott",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "C"
                    ],
                    "last": "Barnard",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "I"
                    ],
                    "last": "Jarvis",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Kucharski",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Munday",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Infection sustained by lineage 401 B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in 402 nasopharyngeal swabs",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Calistri",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Amato",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Puglia",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Cito",
                    "suffix": ""
                },
                {
                    "first": "Di",
                    "middle": [],
                    "last": "Giuseppe",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Danzetta",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "International Journal of Infectious Diseases",
            "volume": "105",
            "issn": "",
            "pages": "753--758",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Effects of a major deletion in the 406 SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational 407 cohort study. The Lancet",
            "authors": [
                {
                    "first": "Fong S-W",
                    "middle": [],
                    "last": "Be",
                    "suffix": ""
                },
                {
                    "first": "Y-H",
                    "middle": [],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "T-M",
                    "middle": [],
                    "last": "Mak",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "W"
                    ],
                    "last": "Ang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "E"
                    ],
                    "last": "Anderson",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "396",
            "issn": "",
            "pages": "603--614",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Genomic characteristics and 409 clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing 410 and hospital-based cohort study. The Lancet Infectious Diseases",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Frampton",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Rampling",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Cross",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Bailey",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Heaney",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Byott",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Changes in symptomatology, 414 reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. 415 The Lancet Public Health",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Graham",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "H"
                    ],
                    "last": "Sudre",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "May",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Antonelli",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Murray",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Varsavsky",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "6",
            "issn": "",
            "pages": "335--380",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Coronavirus (COVID-19) Infection Survey -Office for National Statistics",
            "authors": [],
            "year": 2009,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Assessing transmissibility of SARS-422",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Volz",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mishra",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Chand",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Barrett",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Johnson",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Geidelberg",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "CoV-2 lineage B.1.1.7 in England",
            "authors": [],
            "year": 2021,
            "venue": "Nature",
            "volume": "",
            "issn": "",
            "pages": "1--17",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Circulating SARS-CoV-2 variants B.1.1.7, 501Y.V2, and 424 P.1 have gained ability to utilize rat and mouse Ace2 and altered in vitro sensitivity to neutralizing 425 antibodies and ACE2-Ig. bioRxiv",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Yao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "The B1.351 and P.1 variants 427 extend SARS-CoV-2 host range to mice. bioRxiv",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Montagutelli",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Prot",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Levillayer",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "B"
                    ],
                    "last": "Salazar",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Jouvion",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Conquet",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Reduced antibody cross-reactivity 429 following infection with B.1.1.7 than with parental SARS-CoV-2 strains. bioRxiv",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Faulkner",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Ng",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Harvey",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Hussain",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Greco",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "SARS-CoV-2 lateral flow antigen tests: evaluation of VUI-202012/01",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "36",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "Emergence and rapid 436 spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with 437 multiple spike mutations in South Africa. medRxiv",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Tegally",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Wilkinson",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Giovanetti",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Iranzadeh",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Fonseca",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Giandhari",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Neutralization of 442 viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by 443 convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tada",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "M"
                    ],
                    "last": "Dcosta",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Samanovic-Golden",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Herati",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Cornelius",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Mulligan",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)",
            "authors": [],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "mRNA-1273 vaccine induces 449 neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "P"
                    ],
                    "last": "Werner",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "I"
                    ],
                    "last": "Moliva",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Koch",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Choi",
                    "suffix": ""
                },
                {
                    "first": "Gbe",
                    "middle": [],
                    "last": "Stewart-Jones",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months 452",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "453",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Serious-Safety-Concerns-Through-Up-to-Six-Months-Following-Second-Dose-in-456 Updated-Topline-Analysis-of-Landmark-COVID-19-Vaccine-Study 457",
            "authors": [
                {
                    "first": "-",
                    "middle": [],
                    "last": "Efficacy",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "Evidence for increased breakthrough 458 rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. medRxiv",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Kustin",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Harel",
                    "suffix": ""
                },
                {
                    "first": "U",
                    "middle": [],
                    "last": "Finkel",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Perchik",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Harari",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Tahor",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "CoV2373 Covid-19 Vaccine Against the B.1.351 Variant. medRxiv",
            "authors": [],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF50": {
            "ref_id": "b50",
            "title": "Covid-19 Vaccine against the B.1.351 Variant",
            "authors": [],
            "year": 2021,
            "venue": "New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF51": {
            "ref_id": "b51",
            "title": "Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen 465 assay in an epidemic driven by 501Y.v2 (lineage B.1.351) in the Eastern Cape",
            "authors": [
                {
                    "first": "O",
                    "middle": [
                        "L"
                    ],
                    "last": "Akingba",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Sprong",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "R"
                    ],
                    "last": "Hardie",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "South Africa. medRxiv",
            "volume": "466",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "Model-based 468 estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant. medRxiv",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "M"
                    ],
                    "last": "Coutinho",
                    "suffix": ""
                },
                {
                    "first": "Fmd",
                    "middle": [],
                    "last": "Marquitti",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "S"
                    ],
                    "last": "Ferreira",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "Borges",
                    "suffix": ""
                },
                {
                    "first": "Rlp",
                    "middle": [],
                    "last": "Silva",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Da",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Canton",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF53": {
            "ref_id": "b53",
            "title": "Genomics and 471 epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. medRxiv",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "R"
                    ],
                    "last": "Faria",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "A"
                    ],
                    "last": "Mellan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Whittaker",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "M"
                    ],
                    "last": "Claro",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Candido D Da",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mishra",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "Three-quarters 474 attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "F"
                    ],
                    "last": "Buss",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "A"
                    ],
                    "last": "Prete",
                    "suffix": ""
                },
                {
                    "first": "Cmm",
                    "middle": [],
                    "last": "Abrahim",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mendrone",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Salomon",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Almeida-Neto C De",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Science",
            "volume": "371",
            "issn": "6526",
            "pages": "288--92",
            "other_ids": {}
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "Levels of 477 SARS-CoV-2 Lineage P.1 Neutralization by Antibodies Elicited after Natural Infection and Vaccination 478",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "M"
                    ],
                    "last": "Souza",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Amorim",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Sesti-Costa",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "D"
                    ],
                    "last": "Coimbra",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Toledo-Teixeira Da De",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "L"
                    ],
                    "last": "Parise",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF56": {
            "ref_id": "b56",
            "title": "Social Science Research Network",
            "authors": [],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF57": {
            "ref_id": "b57",
            "title": "Transmission, infectivity, 481 and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike 482 protein mutation. medRxiv",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Garcia-Knight",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "M"
                    ],
                    "last": "Khalid",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Servellita",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "K"
                    ],
                    "last": "Morris",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF58": {
            "ref_id": "b58",
            "title": "Estimation of secondary household 484 attack rates for emergent spike L452R SARS-CoV-2 variants detected by genomic surveillance at a 485 community-based testing site in San Francisco",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Mann",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Mitchell",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "T"
                    ],
                    "last": "Laurie",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Sunshine",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Clin Infect Dis",
            "volume": "486",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1093/cid/ciab283/6206738"
                ]
            }
        },
        "BIBREF59": {
            "ref_id": "b59",
            "title": "A Novel SARS-CoV-2 488 Variant of Concern, B.1.526, Identified in New York. medRxiv",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "K"
                    ],
                    "last": "Annavajhala",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Mohri",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "E"
                    ],
                    "last": "Zucker",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Sheng",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gomez-Simmonds",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF60": {
            "ref_id": "b60",
            "title": "Genome Sequencing by INSACOG shows variants of concern and a Novel variant in India",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF61": {
            "ref_id": "b61",
            "title": "Antibody Resistance of SARS-CoV-2 Variants 492 B.1.351 and B.1.1.7. Nature",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Nair",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Iketani",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "1--9",
            "other_ids": {}
        },
        "BIBREF62": {
            "ref_id": "b62",
            "title": "A SARS-CoV-2 494 lineage A variant (A.23.1) with altered spike has emerged and is dominating the current Uganda 495 epidemic. medRxiv",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "L"
                    ],
                    "last": "Bugembe",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "T"
                    ],
                    "last": "Phan",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ssewanyana",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Semanda",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Nansumba",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Dhaala",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF63": {
            "ref_id": "b63",
            "title": "Increasing frequency 497 of SARS-CoV-2 lineages B.1.1.7, P.1 and P.2 and identification of a novel lineage harboring E484Q and 498 N501T spike mutations in Minas Gerais, Southeast Brazil -SARS-CoV-2 coronavirus",
            "authors": [
                {
                    "first": "Frr",
                    "middle": [],
                    "last": "Moreira",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Bonfim",
                    "suffix": ""
                },
                {
                    "first": "Vev",
                    "middle": [],
                    "last": "Geddes",
                    "suffix": ""
                },
                {
                    "first": "Dag",
                    "middle": [],
                    "last": "Zauli",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Silva J Do",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "B"
                    ],
                    "last": "Lima",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "De",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF65": {
            "ref_id": "b65",
            "title": "CoV-2 in domestic cats imposes a narrow bottleneck",
            "authors": [],
            "year": null,
            "venue": "PLOS Pathogens. 2021 f\u00e9vr",
            "volume": "17",
            "issn": "2",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF66": {
            "ref_id": "b66",
            "title": "Early Release -Novel 505 SARS-CoV-2 Variant Derived from Clade 19B",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Fourati",
                    "suffix": ""
                },
                {
                    "first": "J-W",
                    "middle": [],
                    "last": "Decousser",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Khouider",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "&apos;debi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Demontant",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Trawinski",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Number 5-May 2021 -Emerging 506 Infectious Diseases journal -CDC",
            "volume": "27",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF67": {
            "ref_id": "b67",
            "title": "Evaluating the Effects of SARS-CoV-2 509",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Volz",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Hill",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "T"
                    ],
                    "last": "Mccrone",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Price",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Jorgensen",
                    "suffix": ""
                },
                {
                    "first": "\u00c1",
                    "middle": [],
                    "last": "O&apos;toole",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF69": {
            "ref_id": "b69",
            "title": "The Impact of Mutations in SARS-CoV-2 Spike on Viral 511 Infectivity and Antigenicity",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Nie",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Hao",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell",
            "volume": "182",
            "issn": "5",
            "pages": "1284--1294",
            "other_ids": {}
        },
        "BIBREF70": {
            "ref_id": "b70",
            "title": "Identification of SARS-CoV-2 513 spike mutations that attenuate monoclonal and serum antibody neutralization",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "A"
                    ],
                    "last": "Vanblargan",
                    "suffix": ""
                },
                {
                    "first": "L-M",
                    "middle": [],
                    "last": "Bloyet",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "W"
                    ],
                    "last": "Rothlauf",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "E"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Stumpf",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Cell Host & Microbe",
            "volume": "514",
            "issn": "3",
            "pages": "477--488",
            "other_ids": {}
        },
        "BIBREF71": {
            "ref_id": "b71",
            "title": "Multiple SARS-CoV-2 516 variants escape neutralization by vaccine-induced humoral immunity",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "F"
                    ],
                    "last": "Garcia-Beltran",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "C"
                    ],
                    "last": "Lam",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "S"
                    ],
                    "last": "Denis",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "D"
                    ],
                    "last": "Nitido",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [
                        "H"
                    ],
                    "last": "Garcia",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "M"
                    ],
                    "last": "Hauser",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "298--299",
            "other_ids": {}
        },
        "BIBREF72": {
            "ref_id": "b72",
            "title": "SARS-CoV-2 immune evasion by 519 variant B.1.427/B.1.429. bioRxiv",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Mccallum",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Bassi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "D"
                    ],
                    "last": "Marco",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Walls",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Iulio",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF73": {
            "ref_id": "b73",
            "title": "The localized rise of a B.1.526 variant 521 containing an E484K mutation in New York State. medRxiv",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Lasek-Nesselquist",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Lapierre",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Schneider",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "S"
                    ],
                    "last": "George",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Pata",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF74": {
            "ref_id": "b74",
            "title": "BNT162b2 mRNA Covid-19 Vaccine in a 523 Nationwide Mass Vaccination Setting",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Dagan",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Barda",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Kepten",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Miron",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Perchik",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Katz",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF75": {
            "ref_id": "b75",
            "title": "Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African 525 variant",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Mahase",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "BMJ",
            "volume": "372",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF76": {
            "ref_id": "b76",
            "title": "Janssen Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum 528",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF77": {
            "ref_id": "b77",
            "title": "Efficacy of ChAdOx1 nCoV-19 530 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis 531 of a randomised controlled trial. The Lancet",
            "authors": [
                {
                    "first": "Krw",
                    "middle": [],
                    "last": "Emary",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Golubchik",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "K"
                    ],
                    "last": "Aley",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "V"
                    ],
                    "last": "Ariani",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Angus",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bibi",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "397",
            "issn": "",
            "pages": "1351--62",
            "other_ids": {}
        },
        "BIBREF78": {
            "ref_id": "b78",
            "title": "1.526 SARS-CoV-2 variants 533 identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. 534 bioRxiv",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "M"
                    ],
                    "last": "Dcosta",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "I"
                    ],
                    "last": "Samanovic",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Mulligan",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "R"
                    ],
                    "last": "Landau",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "B"
                    ],
                    "last": "Tada",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "47 acid sequence. The huge number of infected individuals and the high viral load produced during each 48 infection offer many opportunities for SARS-CoV-2 mutations to arise and undergo selection, especially during 49 increasing population immunity. Those mutations, especially when arising on the S-gene coding for the spike 50 (S) protein, may affect both viral entry into targeted cells -mediated by the binding of S to its ACEII receptor -51 and efficacy of antibodies. Because the receptor binding domain (RBD) of S is the main target of neutralizing 52 antibodies[2], and all approved vaccines express a form S, mutations to S and its RBD in particular pose a 53 concern for vaccine effectiveness and transmissibility of SARS-CoV-2. Mutations at the N-terminus are also 54 potentially problematic, as a number of highly potent neutralizing antibodies target this domain[3]. The impact 55 of the mutations occurring in other regions of the genome is less well characterized.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "83 evolutionary pressure due to high exposure rates, or evolution within an intermediate animal host such as 84 minks[4]. Notably, some mutations have arisen independently multiple times.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Common features of the VOCs include multiple mutations in S compared to the Wuhan reference sequence, 86 and at least one mutation in the RBD of S. They are associated with a surge or rebound of the pandemic in 87 countries where they have been identified, particularly in the UK, South Africa and some cities of Brazil. The 88 B.1.1.7, B.1.351, and P.1 variants are now known to have variously established clusters in all continents 89 except Antarctica[7].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "K417N and K417T mutations of the S protein are involved in conformational change and in antibody 110 escape [13,14]. K417N was found to attenuate affinity for ACEII, but this is compensated for by the presence 111 of N510Y, as affinity is still higher than when both mutations are absent[15].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "L452R mutation is within the RBD, and thus may be relevant to transmissibility or immune escape[16], 113 indeed, the L452R mutation has been shown to result in binding-escape from the therapeutic mAb 114 bamlanivimab (LY-CoV555)[17].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "\u220669-70 mutations of the S protein are associated with increased infectivity and decreased sera 116 neutralization[18,19], as well as a S-gene target failure (SGTF) in some multiplex RT-PCR tests[20]. Most 117 tests have built in redundancy by targeting multiple genes, and thus will still detect SARS-CoV-2 if it harbours 118 this mutation.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "Notably, mAbs in development that target conserved epitopes with SARS-CoV-1 are thought to retain their 120 activity against all mutants in S.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "Mutations in the Nucleocapsid (N) protein may pose a potential diagnostic risk, as commercially available 122 antigenic rapid diagnostic tests (Ag-RDTs) detect the presence of N protein[21].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "General antibody neutralization and immune escape remarks: Studies testing specific monoclonal 124 antibodies often report severe reductions or complete escape following mutations to S. Thus VOCs and VOIs 125 J o u r n a l P r e -p r o o f",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": "133SARS-CoV-2 T cell epitopes are not affected by the mutations characterizing the current VOCs[24].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF10": {
            "text": ".1.1.7 or 501Y.V1 or VOC 202012/01 136 Transmissibility/viral load and duration: This VOC is reportedly 43-82% more transmissible[25], with conflicting 137 data suggesting elevated viral loads that persist longer[26], or no significant differences in viral load(VL)[27].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF11": {
            "text": "Notably, implementation of strict public health and social measures successfully reduced transmission. As of 139 March 2021, it accounted for nearly 80% of sequenced cases in Europe, and up to date frequencies can be 140 found at: https://cov-lineages.org/global_report_B.1.1.7.html.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF12": {
            "text": "Symptom presentation and disease severity: It was initially reported to not result in increased severity, and it 142 contains a loss of function mutation in Orf8 that is linked to milder disease[28]. Later reports indicated that it 143 was associated with an increased risk of severe disease and death, but more controlled studies have shown 144 that not to be the case[29,30]. Preliminary results from a self-reported symptom survey reveal that, relative to 145 infections by previous variants, B.1.1.7 infection more frequently causes cough, sore throat, fatigue and 146 myalgia, while anosmia is less common[31].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF13": {
            "text": "Host changes: A small increase in the number of infections in the under 20 age group has been suggested 148 [32], but no conclusions should be drawn given the limited data and multiple risks of bias. In vitro data 149 suggests that this variant may be able to establish infections in rats and mice[33], but this does not appear to 150 be the case in vivo[34].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF14": {
            "text": ". To date, in vitro data 155 suggests escape from the therapeutic mAb etesevimab, while casirivimab, bamlanivimab, and imdevimab 156 retain their activity[33]. Recently, the E484K mutation has been identified in multiple B.1.1.7 sequences 157 (designated VOC202102/02). No relevant data is available for this sub-variant yet, but other E484K bearing158 variants have been linked to reduced vaccine efficacy and escape from some therapeutic mAbs. Interestingly, 159 it was reported that antibodies generated following an infection with B.1.1.7 demonstrated poor cross 160 reactivity against other strains (parental or B.1.351), indicating some degree of asymmetric heterotypic 161 immunity[35]. This raises the possibility that a VOC demonstrating escape from the immune response raised 162 against other strains may also result in those other strains demonstrating escape from the immune response 163 raised against the VOC.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF15": {
            "text": "Impact: This variant results in SGTF in some multiplex RT-PCR tests, but Ag-RDTs are apparently 165 unaffected[36], no other diagnostic issues are known.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF16": {
            "text": "/viral load and duration: B.1.351, which emerged in a background of high HIV prevalence and 168 high rates of population exposure, quickly spread to become the dominant lineage in South Africa[37]. There 169 is currently very little data outside of South Africa on B.1.351, and transmission is reportedly 1.5x higher for 170 this variant[38]. In February of 2021, it reached nearly 80% of sequenced cases in Africa, and up to date 171 frequencies can be found at: https://cov-lineages.org/global_report_B.1.351.html.172Symptom presentation and disease severity: The mortality rate of the second wave was noted to be higher, 173 suggesting the possibility of an increased severity, although differing demographics and overloading of the 174 hospitals are confounding factors[38]. No other data are found in terms of clinical characteristics.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF17": {
            "text": "190 earlier SARS-CoV-2 variants (and were excluded from the analysis), suggesting a strong selection pressure 191 for immune escape. A study conducted in South Africa found a >5% reinfection rate, that did not differ 192 between seropositive and seronegative people, suggesting a lack of protection in response to previous 193 infections[44].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF18": {
            "text": "Concerningly, AstraZeneca's ChAdOx1-nCoV19 vaccine showed only minimal protection against mild or 195 moderate SARS-CoV-2 infection in South Africa, with no data concerning severe disease[45].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF19": {
            "text": "Impact: The Panbio Ag-RDT sensitivity is apparently unaffected[46], no diagnostic issues are 197 known.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF20": {
            "text": "Transmissibility/viral load and duration: The P.1 variant is estimated to be 2.6 times more transmissible[47].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF21": {
            "text": "Notably, the cases due to the P.1 variant in Manaus, a city with high exposure rates, in January represented201 85.4% (n = 41/48) of the identified SARS-CoV-2 sequences[48]. In February of 2021, it reached nearly 40% of 202 sequenced cases in South America, and up to date frequencies can be found at: https://cov-203 lineages.org/global_report_P.1.html.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF22": {
            "text": "Symptom presentation and disease severity: No data.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF23": {
            "text": "Host changes: In vitro data suggests that this variant may be able to establish infections in rats and mice[33], 206 which seems to have been confirmed in vivo[34].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF24": {
            "text": "Immune escape concerns: Similar to the results reported for B.1.351, the efficacy of therapeutic mAbs may be 208 abolished/reduced, including: bamlanivimab, casirivimab, and etesivimab[17,23,33], as well as 209 REGN10989[22]. The pervasiveness may be due to immune escape in the context of a high level of 210 J o u r n a l P r e -p r o o f population immunity[49]. Indeed, modeling suggests up to 28% of the cases in Manaus between Dec 2020 211 and Feb 2021 may have been reinfections[47]. Convalescent plasma or vaccine sera generally show 212 reductions in neutralizing antibody titers, with substantially greater reductions than for B.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF25": {
            "text": "CoronaVax sera, but neutralization titers were low even against non-VOI strains[50]. While reports of 215 reinfection have been reported for P.1, the time frame is not outside the range of intervals seen with earlier 216 variants.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF26": {
            "text": "Impact: No data, but notably, P.1 has 4 mutations in the N gene, suggesting a need for evaluation 218 of Ag-RDT effectiveness.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF27": {
            "text": "Characteristics of disputed VOCs considered to be VOIs by the WHO220 B.1.429/427/Cal20-C221This variant has been classified as a VOC by the CDC, but has not received that designation by the WHO.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF28": {
            "text": "Transmissibility/viral load and duration: These variants are estimated to be 18-24% more transmissible[51], 223 and secondary household attack rate is elevated [52]. Viral load was reported to be approximately 2-fold 224 higher. These variants are increasing in prevalence in southern California, and now account for over 50% of 225 the identified sequences there[16].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF29": {
            "text": "Symptom presentation and disease severity: No data.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF30": {
            "text": "Host changes: No data.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF31": {
            "text": "Impact: No data, but no issues are expected.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF32": {
            "text": "/viral load and duration: This variant has dramatically increased in prevalence in the North-233East USA at the present time, and its detection rate has been steadily increasing[7,53].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF33": {
            "text": "Symptom presentation and disease severity: Patients with this lineage were on average more frequently 235 hospitalized[53], but this may be due to patient age.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF34": {
            "text": "Notably, patients with this lineage were on average older [53].Immune escape concerns: Sub variants carrying the E484K mutation raise concerns of immune escape. The",
            "latex": null,
            "type": "figure"
        },
        "FIGREF35": {
            "text": "This variant contains multiple mutations, notably S477N or E484K near the RBD -but not both 241 at the same time. Researchers referred to it as a VOC, although it has not received this designation from the 242 WHO.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF36": {
            "text": "SARS-CoV-2 Consortium on Genomics has reported detection of a variant with the L452R 245 mutation and the E484Q mutations, but very little data is available at this time. Initially reported as a \"double 246 mutant\" for the presence of 2 prominent RBD mutations (E484Q and L452R), sequences of this lineage 247 lacking E484Q have been found. Preliminary data suggests a reduction in neutralization titers of 248 approximately 2x (Supplementary table 1). The Indian government considers this variant a VOC, but it has not 249 received that designation from the WHO. There are now 3 recognized sub variants of B.1.617: B.1.617.1 (all 250 with E484Q), B.1.617.2 (all with \u2206157,158), and B.1.617.3, although E484Q and \u2206157-158 can also be found 251 in B.1.617 and B.1.617.3. The mutation V382L has also been reported, although its effect is unknown.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF37": {
            "text": "Transmissibility/viral load and duration: Detection of this variant temporally corresponds with a surge in cases,253and this variant reportedly represented 15-20% of the samples as of March 2021[54].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF38": {
            "text": "Symptom presentation and disease severity: No data255Host changes: No data.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF39": {
            "text": "is linked to reductions in neutralizing antibody titers of convalescent plasma or vaccine sera for 268 P.2 (supplemental table 1), and there are reports of reinfection for P.2, but the time frame is not outside the 269 range of intervals seen with earlier variants.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF40": {
            "text": ".23.1, is notable for its lack of the D614G mutation, with a Q613H mutation instead that may be 271 functionally similar. A Ugandan variant replaced previously circulating viruses in Uganda within 2 months, 272 suggesting higher transmissibility, and has already been detected multiple times outside of the country[56].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF41": {
            "text": ".1.621 has been identified in Columbia as having a similar mutation profile (E484K and N501Y) as 274 the VOCs B.1.351 and P.1, but is from a distinct lineage. No further information is available at this time.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF42": {
            "text": "Brazil, a new lineage, provisionally named \"MG\" (with a suggested designation of P.4, but the 276 designation is still pending) has been identified with N501T and E484Q mutations in Minas Gerais[57]. No 277 further information is available at this time.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF43": {
            "text": "VOIs of note 279 B.1.616, 20C variant identified in Brittany, France: First identified during a nosocomial outbreak in a 280 geriatric ward. While many cases were severe, this is not unexpected, given that the age of the patients. This 281 variant has been reported to yield weaker RT-PCR positives, and to have a lower detection rate from 282 nasopharyngeal samples. The current working hypothesis is that this is due to an altered tropism, requiring 283 sampling of the lower respiratory tract. Only one case has been detected outside of Brittany, and that case 284 had a confirmed link to the Brittany cluster. Transmission beyond Brittany therefore seems limited, but notably 285 it does possess a mutation linked to transmission in felines[58].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF44": {
            "text": "286HMN.19B -Henri Mondor 19B variant identified in France: Very little information is available about 287 this variant, but it contains the L452R and N501Y mutations, both of which have been linked to increases in 288 transmissibility. Notably, it belongs to clade 19B, which had become rare since early 2020 and lacks the 289 common D614G mutation, thus its resurgence in this variant may indicate that its mutations confer increased 290 transmissibility[59]. No severe cases were reported, and two cases of reinfections were reported, but the 291 subjects had become seronegative prior to infection. One subject had received the first dose of BNT162b2",
            "latex": null,
            "type": "figure"
        },
        "FIGREF45": {
            "text": "Contributions: EB, IK, PV, IE, LK wrote the first draft of the manuscript and conducted 309 literature research. All authors critically reviewed the manuscript and accepted the final version.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF46": {
            "text": "This work was supported by the Fondation de Bienfaisance du Groupe Pictet, the 311 Fondation Ancrage, the Fondation Priv\u00e9e des H\u00f4pitaux Universitaires de Gen\u00e8ve, the Geneva Center 312 for Emerging Viral Diseases, Faculty of Medicine. The funder had no role in study design, data 313 collection, data analysis, data interpretation or writing of the report. The corresponding author had 314 full access to all the data in the study and had final responsibility for the decision to submit for 315 publication.316Conflict of interest:317The authors declare no conflict of interest.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Host changes: In vitro data suggests that this variant may be able to establish infections in rats and mice[33], 176 which seems to have been confirmed in vivo[34]. Immune escape concerns: Convalescent plasma or vaccine sera generally show reductions in neutralizing 178 antibody titers, with substantially greater reductions than for B.1.1.7 (Supplemental Table 1). This effect is 179 mostly due to the E484K mutation[39]. Notably efficacy, of mAbs approved for COVID-19 treatment may be180 abolished/reduced, such as: etesevimab[17], bamlanivimab, and REGN10989[22]. 181 J o u r n a l P r e -p r o o f Convalescent sera from patients infected with B.1.351 contains highly cross-reactive antibodies able to 182 neutralize other variants, even though antibodies raised against parental viruses are not highly cross reactive 183 with B.1.351[40]. A Moderna press-release suggests that antibody neutralization titers are above levels 184 expected to be protective[41], while a Pfizer press release showed effectiveness with 6 cases of B.1.351 in 185 the control group and 0 in the vaccinated group[42]. Contrastingly, a study in Israel found that infections in 186 vaccinated individuals were 8 times more likely to be caused by B.1.351 than in unvaccinated individuals, suggesting reduced vaccine efficacy against B.1.351[43]. Vaccine studies have generally found decreased 188 efficacy in South Africa, where >90% of the cases were B.1.351, relative to in the US",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Naming conventions and number of mutations of the main three variants of concern (VOC)",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Mutations of selected new SARS-CoV-2 variants (only S mutations shown) compared to the Wuhan 327reference sequence: Green indicates the mutation is present, red that it is not, and grey that it is sometimes present",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "Clinical Observations for new SARS-CoV-2 variants 329 J o u r n a l P r e -p r o o f",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "Effects of the different variants on therapeutics and vaccines 331Vaccine efficacy is given as efficacy against symptomatic infection unless otherwise specified) 332 70% efficacy vs B.1.1.7 vs 81% against non-B.1.1.7[69]10% efficacy against mild and moderate disease in young people, no data against severe disease[45]",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}